Characterisation of responders to Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer using quantitative PSMA-PET-derived parameters (EANM 2026) - Sep 29, 2026 - Abstract #EP-0469; "PSMA-PET-derived MTV was associated with both PFS and OS and improved prognostic discrimination beyond molecular subtype alone. These findings suggest that quantitative PSMA-PET may help refine patient selection for ICI."
Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
T. van Bergen 1; S. van Wilpe 2; T. F. W. Soeterik 3; C. A. T. van den Berg 1; A. J. A. T. Braat 4; N. Mehra 2
|